While cannabis investors focus on the usual suspects, Verano Holdings has quietly built one of the most diversified cultivation and retail footprints in the country.
The Chicago-based MSO operates in 13 states with 115+ retail locations, making it the fourth-largest U.S. cannabis company by revenue. Yet VRNO still trades at a significant discount to peers like Trulieve and Curaleaf.
Why the Discount?
Verano’s valuation gap stems from:
- Leverage concerns: The company carries higher debt levels following aggressive expansion
- Brand recognition: Less consumer-facing brand equity compared to Cookie or Rythm
- Illiquidity: OTC trading limits institutional participation
The Bull Case Strengthens
Recent operational improvements tell a different story. Q4 2025 results showed:
- Adjusted EBITDA of $42M—first positive quarter in 6
- Illinois revenue up 34% YoY as adult-use momentum continues
- New Jersey dispensaries hitting revenue run rates ahead of projections
Management has also committed to debt reduction, with a $100M+ paydown scheduled for H1 2026.
What Investors Should Know
Verano represents a classic “sum of parts” opportunity. Each state operation could theoretically be worth more as a standalone entity given current multi-state operator multiples. The company’s Midwest concentration—often viewed as a weakness—could become a strategic advantage as these states legalize recreational use.
Track VRNO’s performance and fundamentals on Weedstock’s Verano Holdings page.